Juno Therapeutics (JUNO) Tops Q3 EPS by 6c

Juno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.73), $0.06 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $16.03 million.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c